As motesanib, pazopanib (GW786034) is a VEGFR1, 2, 3, PDGFR and c-Kit inhibitor, approved for the treatment of renal cell carcinoma [114], but, contrary to sumatinib, it does not induce apoptosis in human renal cell carcinoma cell lines in vitro [115]. This evidence concerns the gene PDGFRB and renal cell carcinoma.